PH12015501024A1 - Bendamustine derivatives and methods of using same - Google Patents
Bendamustine derivatives and methods of using sameInfo
- Publication number
- PH12015501024A1 PH12015501024A1 PH12015501024A PH12015501024A PH12015501024A1 PH 12015501024 A1 PH12015501024 A1 PH 12015501024A1 PH 12015501024 A PH12015501024 A PH 12015501024A PH 12015501024 A PH12015501024 A PH 12015501024A PH 12015501024 A1 PH12015501024 A1 PH 12015501024A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- same
- bendamustine
- bendamustine derivatives
- derivatives
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical class ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 229960002707 bendamustine Drugs 0.000 abstract 1
- -1 bendamustine amides Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725213P | 2012-11-12 | 2012-11-12 | |
| US201361776951P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/069550 WO2014075035A1 (en) | 2012-11-12 | 2013-11-12 | Bendamustine derivatives and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015501024A1 true PH12015501024A1 (en) | 2015-07-27 |
Family
ID=49667594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015501024A PH12015501024A1 (en) | 2012-11-12 | 2015-05-07 | Bendamustine derivatives and methods of using same |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US9452988B2 (enExample) |
| EP (1) | EP2917183A1 (enExample) |
| JP (1) | JP6262246B2 (enExample) |
| KR (1) | KR20150086308A (enExample) |
| AR (1) | AR093457A1 (enExample) |
| AU (1) | AU2013342015B2 (enExample) |
| BR (1) | BR112015010501A2 (enExample) |
| CA (1) | CA2890462A1 (enExample) |
| CL (1) | CL2015001246A1 (enExample) |
| EA (1) | EA029706B1 (enExample) |
| HK (2) | HK1215701A1 (enExample) |
| IL (1) | IL238662A (enExample) |
| MX (1) | MX2015005805A (enExample) |
| PH (1) | PH12015501024A1 (enExample) |
| SG (1) | SG11201503560TA (enExample) |
| TW (1) | TWI598341B (enExample) |
| WO (1) | WO2014075035A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE044025T2 (hu) | 2010-05-20 | 2019-09-30 | Array Biopharma Inc | Makrociklusos vegyületek mint TRK-kináz inhibitorok |
| CA2890462A1 (en) | 2012-11-12 | 2014-05-15 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
| WO2014164957A1 (en) * | 2013-03-12 | 2014-10-09 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
| WO2018013783A1 (en) * | 2016-07-13 | 2018-01-18 | Cephalon, Inc. | Pharmaceutical prodrugs and methods of their preparation and use |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN117281803A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US7089218B1 (en) | 2004-01-06 | 2006-08-08 | Neuric Technologies, Llc | Method for inclusion of psychological temperament in an electronic emulation of the human brain |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| AU2002239405A1 (en) | 2000-12-01 | 2002-06-11 | Enzon, Inc. | Tetrapartate prodrugs |
| AU2003227147A1 (en) * | 2002-04-05 | 2003-10-27 | Universite De Montreal | Stealthy polymeric biodegradable nanospheres and uses thereof |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| CN101878024B (zh) * | 2007-11-28 | 2014-04-09 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2889029A1 (en) | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| US9149441B2 (en) * | 2008-09-29 | 2015-10-06 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| CN102177140B (zh) | 2008-10-08 | 2016-01-27 | 赛福伦公司 | 用于制备苯达莫司汀的方法 |
| BRPI0922806B8 (pt) * | 2008-12-03 | 2021-05-25 | Astellas Deutschland Gmbh | composição farmacêutica oral compreendendo bendamustina |
| EA031793B1 (ru) | 2010-06-02 | 2019-02-28 | Астеллас Дойчланд Гмбх | Пероральные лекарственные формы бендамустина |
| TWI578997B (zh) | 2010-06-04 | 2017-04-21 | 輝瑞疫苗有限責任公司 | 用於預防或治療菸鹼成癮之共軛體 |
| CN101966158A (zh) | 2010-09-28 | 2011-02-09 | 上海丽思化工科技有限公司 | 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法 |
| US20130217888A1 (en) | 2010-11-01 | 2013-08-22 | Shailpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
| DE102010055499A1 (de) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
| AU2012253571A1 (en) | 2011-05-09 | 2014-01-09 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2012158776A2 (en) | 2011-05-17 | 2012-11-22 | University Of South Alabama | Combination therapy for treatment of cancer |
| CN104011029B (zh) | 2011-09-26 | 2016-06-08 | 费森尤斯卡比肿瘤学有限公司 | 一种制备盐酸苯达莫司汀的改进方法 |
| EP2656843B1 (en) | 2012-04-26 | 2015-03-18 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
| MX365192B (es) | 2012-06-19 | 2019-05-23 | Synbias Pharma Ag | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. |
| CA2881440C (en) | 2012-08-10 | 2022-05-17 | University Of North Texas Health Science Center | Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
| CA2890462A1 (en) * | 2012-11-12 | 2014-05-15 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
-
2013
- 2013-11-12 CA CA2890462A patent/CA2890462A1/en not_active Abandoned
- 2013-11-12 AU AU2013342015A patent/AU2013342015B2/en not_active Ceased
- 2013-11-12 EP EP13795940.9A patent/EP2917183A1/en not_active Withdrawn
- 2013-11-12 US US14/442,088 patent/US9452988B2/en not_active Expired - Fee Related
- 2013-11-12 HK HK16100090.1A patent/HK1215701A1/zh unknown
- 2013-11-12 BR BR112015010501A patent/BR112015010501A2/pt not_active IP Right Cessation
- 2013-11-12 EA EA201590925A patent/EA029706B1/ru not_active IP Right Cessation
- 2013-11-12 KR KR1020157015682A patent/KR20150086308A/ko not_active Withdrawn
- 2013-11-12 MX MX2015005805A patent/MX2015005805A/es unknown
- 2013-11-12 SG SG11201503560TA patent/SG11201503560TA/en unknown
- 2013-11-12 TW TW102140964A patent/TWI598341B/zh not_active IP Right Cessation
- 2013-11-12 JP JP2015541995A patent/JP6262246B2/ja not_active Expired - Fee Related
- 2013-11-12 HK HK16100891.2A patent/HK1212977A1/zh unknown
- 2013-11-12 AR ARP130104160A patent/AR093457A1/es unknown
- 2013-11-12 WO PCT/US2013/069550 patent/WO2014075035A1/en not_active Ceased
-
2015
- 2015-04-29 US US14/699,965 patent/US9150517B2/en not_active Expired - Fee Related
- 2015-05-06 IL IL238662A patent/IL238662A/en not_active IP Right Cessation
- 2015-05-07 PH PH12015501024A patent/PH12015501024A1/en unknown
- 2015-05-08 CL CL2015001246A patent/CL2015001246A1/es unknown
- 2015-05-13 US US14/711,747 patent/US9149464B2/en not_active Expired - Fee Related
- 2015-09-28 US US14/868,278 patent/US20160016912A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,968 patent/US9630926B2/en not_active Expired - Fee Related
-
2017
- 2017-03-10 US US15/456,439 patent/US9913827B2/en not_active Expired - Fee Related
-
2018
- 2018-01-24 US US15/879,130 patent/US20180147186A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501024A1 (en) | Bendamustine derivatives and methods of using same | |
| PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
| IN2014MN02652A (enExample) | ||
| IN2014MN02598A (enExample) | ||
| IN2014MN02657A (enExample) | ||
| PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
| TN2015000380A1 (en) | Heterocyclic compounds and their uses | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2015DN01156A (enExample) | ||
| IN2014MN02658A (enExample) | ||
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MY174188A (en) | Heterocyclyl compounds | |
| IN2015DN01119A (enExample) | ||
| GB201209587D0 (en) | Therapeutic compounds | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
| PH12015500399A1 (en) | Azaindolines | |
| MX2013014398A (es) | Derivados de sulfonamida heterociclicos. | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| IN2013MU02813A (enExample) | ||
| IN2013CH03945A (enExample) |